Literature DB >> 20000375

Parallel Synthesis of bis-heterocyclic isoxazolylmethyl- and isoxazolinylmethylpyrazoles.

Liping Meng1, Beth A Lorsbach, Thomas C Sparks, James C Fettinger, Mark J Kurth.   

Abstract

The solution-phase parallel synthesis of a 136-member library of isoxazol(in)e-CH(2)-pyrazoles is described. X-ray crystallographic structure determination verified the regioselectivities of the N-alkylation and nitrile oxide 1,3-dipolar cycloaddition steps. The construction of these pharmaceutically relevant heterocycles on solid support under microwave irradiation is also demonstrated. The resulting library of drug-like compounds has been added to the National Institutes of Health repository (approximately 10 mg of each with >or=90% purity) for pilot-scale biomedical studies with bioassay data available at the National Center for Biotechnology Information PubChem database. A subset of these compounds has been broadly screened by Dow AgroSciences for herbicidal, fungicidal, and insecticidal activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20000375     DOI: 10.1021/cc900133k

Source DB:  PubMed          Journal:  J Comb Chem        ISSN: 1520-4766


  3 in total

1.  Solid Phase Synthesis of Isoxazole and Isoxazoline-carboxamides via [2+3]-Dipolar Cycloaddition Using Resin-bound Alkynes or Alkenes.

Authors:  Sureshbabu Dadiboyena; Adel Nefzi
Journal:  Tetrahedron Lett       Date:  2012-04-18       Impact factor: 2.415

2.  Improved synthesis of 3-aryl isoxazoles containing fused aromatic rings.

Authors:  Yousef R Mirzaei; Matthew J Weaver; Scott A Steiger; Alison K Kearns; Mariusz P Gajewski; Kevin C Rider; Howard D Beall; N R Natale
Journal:  Tetrahedron       Date:  2012-09-25       Impact factor: 2.457

3.  Heterocycle-heterocycle strategies: (2-nitrophenyl)isoxazole precursors to 4-aminoquinolines, 1H-indoles, and quinolin-4(1H)-ones.

Authors:  Keith C Coffman; Teresa A Palazzo; Timothy P Hartley; James C Fettinger; Dean J Tantillo; Mark J Kurth
Journal:  Org Lett       Date:  2013-04-04       Impact factor: 6.005

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.